No Data
No Data
Express News | NYSE Order Imbalance 68931.0 Shares on Sell Side
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Novartis Boasts Scemblix Beats Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Novartis Reports Positive Phase 3 Data for Remibrutinib for Chronic Hives
Novartis' Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety
On Friday, Novartis AG (NYSE:NVS) released new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in chronic spontaneous
Novartis Scemblix Phase III Data Shows Superior Efficacy With A Favorable Safety And Tolerability Profile Vs. Standard-Of-Care TKIs In Adults With Newly Diagnosed CML
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix (asciminib) demonstrated superior MMR rates at week 48 vs. investigator-
No Data